Influenza A Infections - Epidemiology Forecast - 2036

Influenza A Insights and Trends

• Influenza A is a highly transmissible respiratory infection and the only influenza type known to cause pandemics, with widespread susceptibility due to limited pre-existing immunity in populations.
• Influenza A epidemiology across the 7MM (United States, EU4, the United Kingdom, and Japan) is analyzed from 2022 to 2036, segmented by total vaccinated population, vaccine failure cases, total influenza A positive cases, and strain-specific distribution.
• In the United States, vaccination coverage in 2025 was highest ~140 million among adults aged 18-49 years and lowest among pregnant women ~70 million, with population segmentation across pediatric, adolescent, adult, and elderly groups.
• In 2025, the influenza vaccine failure rate in the United States was estimated at ~120 million, indicating a substantial proportion of vaccinated individuals remained susceptible to infection.
• In Japan, it was observed that in Japan according to the Ministry of Health, Labour and Welfare, the average approximately 196,895 weekly influenza cases were reported in November 2025, corresponding to an average of 51.12 cases per medical institution, indicating high epidemic intensity.

Influenza A Sarcoma Forecast in the United states

• 2025 Total Infleunza A vaccinated pool: ~190 million
• Infleunza A Growth Rate (2026-2036): 2.6% CAGR

DelveInsight's 'Infleunza A - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Influenza A Understanding and Diagnosis Algorithm

Influenza A Overview

Influenza A is a highly contagious respiratory infection caused by influenza A viruses, which are classified into subtypes based on hemagglutinin (H) and neuraminidase (N) proteins, with A(H1N1) and A(H3N2) being the most commonly circulating strains in humans. Clinically, Influenza A presents with symptoms ranging from mild (fever, cough, sore throat, and fatigue) to severe complications such as pneumonia and respiratory distress, particularly in high-risk populations including the elderly and individuals with underlying conditions.

Influenza A Diagnosis

Diagnosis of Influenza virus, including Influenza A, is typically based on clinical symptoms and can be confirmed with laboratory tests. Healthcare providers often use Rapid Influenza Diagnostic Tests (RIDTs), which detect viral antigens in respiratory samples and provide results within minutes. More accurate methods, such as Reverse Transcription-Polymerase Chain Reaction (RT-PCR), are used to confirm the virus type and subtype, especially during outbreaks or severe cases. In some situations, viral culture or immunofluorescence tests may also be performed, though these take longer. Early and accurate diagnosis is important for proper treatment and to help prevent the spread of the virus. Rapid molecular assays are a new kind of molecular influenza diagnostic test for upper respiratory tract specimens with high sensitivity and specificity. Two FDA-cleared rapid molecular assays are available in the United States. Rapid molecular assays can provide results in approximately 20 min.

Influenza A Epidemiology

Key Findings from Influenza A Epidemiological Analysis and Forecast

• The Influenza A epidemiology analysis covers both historical and forecasted trends across the 7MM (United States, EU4-Germany, France, Italy, and Spain and the United Kingdom and Japan) from 2020 to 2036, segmented by total vaccinated population, Total vaccine failure cases, total influenza A positive cases, and strain-specific distribution.
• In the United States, the vaccinated population was highest among adults aged 18-49 years, while the lowest vaccination uptake was observed in pregnant women in 2024; overall, the vaccinated pool was segmented across children (0-4, 5-12 years), adolescents (13-17 years), adults (18-49, 50-64, >=65 years), and pregnant women.
• In 2024, the influenza vaccine failure rate in the United States was estimated to be approximately 70%, indicating a substantial proportion of vaccinated individuals remained susceptible to infection.
• In Japan, it was observed that in Japan according to the Ministry of Health, Labour and Welfare, the average approximately 196,895 weekly influenza cases were reported in November 2025, corresponding to an average of 51.12 cases per sentinel medical institution, indicating high epidemic intensity.
• In Europe, influenza A (H1N1)pdm09 emerged as the predominant subtype in 2024, accounting for approximately 57% to 93% of all influenza A cases, as reported by the European Respiratory Virus Surveillance Summary (ERVISS) (2025).
• In the United States, the total number of influenza A positive cases is projected to increase over the study period from 2022 to 2036, reflecting a rising disease burden over time.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of Influenza A, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Influenza A Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Influenza A? What will be the growth opportunities across the 7MM concerning the patient population with Influenza A?
• What is the historical and forecasted Influenza A patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.